|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen YL, Cheng WF, Chang MC, Lin HW, Huang
CT, Chien CL and Chen CA: Interferon-gamma in ascites could be a
predictive biomarker of outcome in ovarian carcinoma. Gynecol
Oncol. 131:63–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
White KL, Schildkraut JM, Palmieri RT,
Iversen ES Jr, Berchuck A, Vierkant RA, Rider DN, Charbonneau B,
Cicek MS, Sutphen R, et al Ovarian Cancer Association Consortium:
Ovarian cancer risk associated with inherited inflammation-related
variants. Cancer Res. 72:1064–1069. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koyanagi T, Suzuki Y, Saga Y, Machida S,
Takei Y, Fujiwara H, Suzuki M and Sato Y: In vivo delivery of siRNA
targeting vasohibin-2 decreases tumor angiogenesis and suppresses
tumor growth in ovarian cancer. Cancer Sci. 104:1705–1710. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsofack SP, Meunier L, Sanchez L, Madore
J, Provencher D, Mes-Masson AM and Lebel M: Low expression of the
X-linked ribosomal protein S4 in human serous epithelial ovarian
cancer is associated with a poor prognosis. BMC Cancer. 13:3032013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marsh S: Pharmacogenomics of
taxane/platinum therapy in ovarian cancer. Int J Gynecol Cancer.
19(Suppl 2): S30–S34. 2009. View Article : Google Scholar
|
|
9
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livingstone C: IGF2 and cancer. Endocr
Relat Cancer. 20:R321–R339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu H, Mistry J, Nicar MJ, Khosravi MJ,
Diamandis A, van Doorn J and Juul A: Insulin-like growth factors
(IGF-I, free IGF-I and IGF-II) and insulin-like growth factor
binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood
circulation. J Clin Lab Anal. 13:166–172. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raynaud-Simon A: Levels of plasma
insulin-like growth factor I (IGF I), IGF II, IGF binding proteins,
type 1 IGF receptor and growth hormone binding protein in
community-dwelling elderly subjects with no malnutrition and no
inflammation. J Nutr Health Aging. 7:267–273. 2003.PubMed/NCBI
|
|
13
|
O’Dell SD and Day IN: Insulin-like growth
factor II (IGF-II). Int J Biochem Cell Biol. 30:767–771. 1998.
View Article : Google Scholar
|
|
14
|
Liu L, Greenberg S, Russell SM and Nicoll
CS: Effects of insulin-like growth factors I and II on growth and
differentiation of transplanted rat embryos and fetal tissues.
Endocrinology. 124:3077–3082. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu H and Rohan T: Role of the insulin-like
growth factor family in cancer development and progression. J Natl
Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El Tayebi HM, Salah W, El Sayed IH, Salam
EM, Zekri AR, Zayed N, Salem ES, Esmat G and Abdelaziz AI:
Expression of insulin-like growth factor-II, matrix
metalloproteinases, and their tissue inhibitors as predictive
markers in the peripheral blood of HCC patients. Biomarkers.
16:346–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui
H and Casson AG: Loss of imprinting of the insulin-like growth
factor II (IGF2) gene in esophageal normal and adenocarcinoma
tissues. Carcinogenesis. 30:2117–2122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kalla Singh S, Tan QW, Brito C, De León M,
Garberoglio C and De León D: Differential insulin-like growth
factor II (IGF-II) expression: A potential role for breast cancer
survival disparity. Growth Horm IGF Res. 20:162–170. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng J, Dong Y, Li C, Zuo W, Meng G, Xu C
and Li J: Decreased expression of C10orf10 and its prognostic
significance in human breast cancer. PLoS One. 9:e997302014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY,
Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of
regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol.
25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han F, Liu W, Jiang X, Shi X, Yin L, Ao L,
Cui Z, Li Y, Huang C, Cao J, et al: SOX30, a novel epigenetic
silenced tumor suppressor, promotes tumor cell apoptosis by
transcriptional activating p53 in lung cancer. Oncogene. Dec
1–2014.Epub ahead of print. View Article : Google Scholar
|
|
22
|
Han F, Dong Y, Liu W, Ma X, Shi R, Chen H,
Cui Z, Ao L, Zhang H, Cao J, et al: Epigenetic regulation of sox30
is associated with testis development in mice. PLoS One.
9:e972032014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
El-Badry OM, Romanus JA, Helman LJ, Cooper
MJ, Rechler MM and Israel MA: Autonomous growth of a human
neuroblastoma cell line is mediated by insulin-like growth factor
II. J Clin Invest. 84:829–839. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhan S, Shapiro DN and Helman LJ:
Activation of an imprinted allele of the insulin-like growth factor
II gene implicated in rhabdomyosarcoma. J Clin Invest. 94:445–448.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tricoli JV, Rall LB, Karakousis CP,
Herrera L, Petrelli NJ, Bell GI and Shows TB: Enhanced levels of
insulin-like growth factor messenger RNA in human colon carcinomas
and liposarcomas. Cancer Res. 46:6169–6173. 1986.PubMed/NCBI
|
|
27
|
Cariani E, Lasserre C, Seurin D, Hamelin
B, Kemeny F, Franco D, Czech MP, Ullrich A and Brechot C:
Differential expression of insulin-like growth factor II mRNA in
human primary liver cancers, benign liver tumors, and liver
cirrhosis. Cancer Res. 48:6844–6849. 1988.PubMed/NCBI
|
|
28
|
Gicquel C, Bertagna X, Schneid H,
Francillard-Leblond M, Luton JP, Girard F and Le Bouc Y:
Rearrangements at the 11p15 locus and overexpression of
insulin-like growth factor-II gene in sporadic adrenocortical
tumors. J Clin Endocrinol Metab. 78:1444–1453. 1994.PubMed/NCBI
|
|
29
|
Yoon AJ, Zavras AI, Chen MK, Lin CW and
Yang SF: Association between Gly1619ARG polymorphism of IGF2R
domain 11 (rs629849) and advanced stage of oral cancer. Med Oncol.
29:682–685. 2012. View Article : Google Scholar
|
|
30
|
Hoyo C, Murphy SK, Schildkraut JM, Vidal
AC, Skaar D, Millikan RC, Galanko J, Sandler RS, Jirtle R and Keku
T: IGF2R genetic variants, circulating IGF2 concentrations and
colon cancer risk in African Americans and Whites. Dis Markers.
32:133–141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Couvert P, Carrié A, Tezenas du Montcel S,
Vaysse J, Sutton A, Barget N, Trinchet JC, Beaugrand M, Ganne N,
Giral P, et al: Insulin-like growth factor 2 gene methylation in
peripheral blood mononuclear cells of patients with hepatitis C
related cirrhosis or hepatocellular carcinoma. Clin Res Hepatol
Gastroenterol. 36:345–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Randhawa GS, Cui H, Barletta JA,
Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB,
Champlin RC and Feinberg AP: Loss of imprinting in disease
progression in chronic myelogenous leukemia. Blood. 91:3144–3147.
1998.PubMed/NCBI
|
|
33
|
Bates P, Fisher R, Ward A, Richardson L,
Hill DJ and Graham CF: Mammary cancer in transgenic mice expressing
insulin-like growth factor II (IGF-II). Br J Cancer. 72:1189–1193.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moorehead RA, Sanchez OH, Baldwin RM and
Khokha R: Transgenic overexpression of IGF-II induces spontaneous
lung tumors: a model for human lung adenocarcinoma. Oncogene.
22:853–857. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rogler CE, Yang D, Rossetti L, Donohoe J,
Alt E, Chang CJ, Rosenfeld R, Neely K and Hintz R: Altered body
composition and increased frequency of diverse malignancies in
insulin-like growth factor-II transgenic mice. J Biol Chem.
269:13779–13784. 1994.PubMed/NCBI
|
|
36
|
Pravtcheva DD and Wise TL: Metastasizing
mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J exp
Zool. 281:43–57. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bartke A, Chandrashekar V, Bailey B,
Zaczek D and Turyn D: Consequences of growth hormone (GH)
overexpression and GH resistance. Neuropeptides. 36:201–208. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang GS, Brouwer-visser J, Ramirez MJ,
Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER,
Goldberg GL, et al: Insulin-like growth factor 2 expression
modulates Taxol resistance and is a candidate biomarker for reduced
disease-free survival in ovarian cancer. Clin Cancer Res.
16:2999–3010. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brouwer-Visser J, Lee J, McCullagh K,
Cossio MJ, Wang Y and Huang GS: Insulin-like growth factor 2
silencing restores taxol sensitivity in drug resistant ovarian
cancer. PLoS One. 9:e1001652014. View Article : Google Scholar : PubMed/NCBI
|
